A senior professor from Jamia Millia Islamia University told ThePrint that the tenure of most of the university’s partnerships was either over or was on the verge of expiry.

The companies Vaxcyte, Generate Biomedicines, and Immunic bagged the biggest biotech funding rounds overall in February 2026.

Preview this article 1 min The company wants to use the treatment for age-related vision loss. Biotech's treatment shows ...

Protein activity can be precisely regulated via subtle changes in temperature using heat-sensitive switches. Underlying this ...

After losing his beloved dog of 13 years, Tom Rubython sold his sports cars and travelled to South Korea to fund a rare genetic procedure ...

On Thursday, Elon Musk's comment revived public fascination with whether modern biotechnology could ever bring extinct ...

February 2026 saw a major biopharma acquisition, four key buyouts, and licensing deals in antibodies, small molecules, and ...

A viral social media exchange involving Elon Musk has revived debate about whether science could one day recreate extinct ...

Tenaya leverages “human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) with high-throughput in vitro screening, imaging analysis, and machine learning algorithms” to identify new ...

Kiana Aran, Associate Professor of Bioengineering and Medicine at the University of California San Diego, spoke with Rudra Chaudhuri, Vice President of the Observer Research Foundation, at the Raisina ...

Cas9, Transcription Activator-Like Effector Nucleases (TALENs), and Zinc-Finger nucleases (ZFNs) have demonstrated great utility, primarily for genetic knock-out applications, none have been adopted ...

Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) ("Calidi” or the "Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announced the closing of its ...